We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

167 hedge funds and large institutions have $2.37B invested in Agios Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 84 increasing their positions, 34 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 34

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

7% more funds holding

Funds holding: 156 → 167 (+11)

1% less capital invested

Capital invested by funds: $2.39B → $2.37B (-$19.4M)

1.34% less ownership

Funds ownership: 97.02% → 95.68% (-1.3%)

38% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $17.9M

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
167
Holders Change
+11
Holders Change %
+7.05%
% of All Funds
4.16%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.1%
New
28
Increased
84
Reduced
34
Closed
16
Calls
$11.1M
Puts
$17.9M
Net Calls
-$6.77M
Net Calls Change
-$3.2M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$45.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$43.7M
3
Invesco
Invesco
Georgia
+$34.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$31.6M
5
BlackRock
BlackRock
New York
+$26M

Top Sellers

1
FP
Flagship Pioneering
Massachusetts
-$56.4M
2
RG
Redmile Group
California
-$11.3M
3
CGT
Capital Guardian Trust
California
-$7.88M
4
GTC
Ghost Tree Capital
New York
-$7.3M
5
Capital Fund Management (CFM)
Capital Fund Management (CFM)
France
-$5.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$372M +$45.8M +895,584 +14%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$347M +$43.7M +854,891 +15%
Vanguard Group
3
Vanguard Group
Pennsylvania
$165M +$31.6M +617,379 +24%
Capital International Investors
4
Capital International Investors
California
$161M +$16.6M +325,310 +12%
BB
5
BB Biotech
Switzerland
$148M +$1.53M +30,000 +1%
BlackRock
6
BlackRock
New York
$138M +$26M +508,306 +23%
ClearBridge Investments
7
ClearBridge Investments
New York
$78.9M -$266K -5,197 -0.3%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$77.3M +$5.08M +99,357 +7%
State Street
9
State Street
Massachusetts
$67M +$4.97M +97,220 +8%
Invesco
10
Invesco
Georgia
$51M +$34.3M +670,703 +209%
First Trust Advisors
11
First Trust Advisors
Illinois
$50.1M +$17.1M +334,291 +52%
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$49M +$4.25M +83,130 +10%
CGT
13
Capital Guardian Trust
California
$40.2M -$7.88M -154,079 -16%
CWAM
14
Columbia Wanger Asset Management
Illinois
$39.6M +$8.12M +158,856 +26%
AG
15
Artal Group
Luxembourg
$36M -$2.56M -50,000 -7%
RG
16
Redmile Group
California
$35M -$11.3M -221,413 -25%
Goldman Sachs
17
Goldman Sachs
New York
$35M +$1.63M +31,969 +5%
Capital World Investors
18
Capital World Investors
California
$34.1M – – –
Norges Bank
19
Norges Bank
Norway
$31.8M -$531K -10,393 -2%
Janus Henderson Group
20
Janus Henderson Group
United Kingdom
$20.4M +$20.3M +396,954 New
AC
21
Ascend Capital
California
$19.7M +$19.5M +382,348 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$17.8M +$4.22M +82,490 +31%
CI
23
Capital International
California
$17.5M -$337K -6,600 -2%
EAM
24
Eventide Asset Management
Massachusetts
$15.5M – – –
Brown Advisory
25
Brown Advisory
Maryland
$13.8M +$249K +4,861 +2%
1
2 3 4 5

AGIO Hedge Fund Activity: Q2 2017 in Review

167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2017, worth a combined $2.37B — down 0.81% from $2.39B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new AGIO positions and 16 closed out — a net gain of 12 holders — while 84 added to existing stakes and 34 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $45.8M. The largest seller was Flagship Pioneering, exiting entirely with an estimated $56.4M sold.

  • 167 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2017, up from 156 in Q1 2017.
  • Funds reported $2.37B of Agios Pharmaceuticals stock for Q2 2017, down 0.81% quarter-over-quarter.
  • 28 funds opened new Agios Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of +12 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2017 was Fidelity Investments, an estimated $45.8M added.
  • The largest Agios Pharmaceuticals seller in Q2 2017 was Flagship Pioneering, an estimated $56.4M sold.

Based on aggregated 13F filings for Q2 2017.